Durata Therapeutics (DRTX) Reports DISCOVER 1 Phase 3 Met Primary, Secondary Endpoint
Tweet Send to a Friend
Durata Therapeutics, Inc. (Nasdaq: DRTX) today announced additional preliminary, top-line results for its DISCOVER 1 Phase 3 study of dalbavancin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
